SanofiAventis

SanofiAventis, commonly referred to as Sanofi-Aventis, was a French multinational pharmaceutical company formed in 2004 through the merger of Sanofi-Synthélabo and Aventis. In 2011, the company adopted the simpler name Sanofi as part of a global rebranding and to reflect a broader corporate footprint.

The business engaged in the development, manufacture, and marketing of medicines across a range of therapeutic areas, including diabetes, cardiovascular disease, oncology, immunology, and rare diseases. It also operated Sanofi Pasteur, its global vaccines unit, and offered consumer healthcare products. The company pursued research and development activities worldwide and maintained manufacturing sites in multiple regions.

Notable products associated with the SanofiAventis era include Lantus (insulin glargine) for diabetes management, Lovenox (enoxaparin) as an anticoagulant, and Plavix (clopidogrel) for cardiovascular protection (developed in collaboration with partners). Through its vaccines unit, Sanofi Pasteur, the company became a leading supplier of influenza vaccines and other immunizations for global public health.

Headquartered in Paris, Sanofi operated as a global enterprise with research, development, and manufacturing activities in numerous countries and a presence in diverse markets. It was publicly traded on the Euronext Paris exchange and was a constituent of major indices such as the CAC 40. Since the 2011 rebranding, the company has continued to expand its pharmaceutical and vaccine portfolio, maintaining its position as a major player in the global drug industry.